Mining mouse behavior for patterns predicting psychiatric drug classification

Psychopharmacology

Volumn 231, Issue 1, 2014, Pages 231-242

  Kafkafi, Neri ^a   Mayo, Cheryl L ^b   Elmer, Greg I ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Behavioral phenotyping; Open field; SEE; Spatial behavior

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; APOMORPHINE; COCAINE; MAZINDOL; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; NEUROLEPTIC AGENT; NOMIFENSINE; OPIATE; PSYCHEDELIC AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG DATABASE; FEASIBILITY STUDY; HIGH THROUGHPUT SCREENING; MALE; MENTAL DISEASE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOPHARMACOLOGY; VALIDATION STUDY;

ALGORITHMS; ANIMALS; BEHAVIOR, ANIMAL; DATA MINING; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; FEASIBILITY STUDIES; MALE; MENTAL DISORDERS; MICE; MICE, INBRED C57BL; MODELS, PSYCHOLOGICAL; MOTOR ACTIVITY; PHARMACEUTICAL VEHICLES; PREDICTIVE VALUE OF TESTS; PSYCHOTROPIC DRUGS;

EID: 84891837127     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3230-6     Document Type: Article

References (34)

1. Agid Y, Buzsáki G, Diamond DM, Frackowiak R, Giedd J, Girault JA, Grace A, Lambert JJ, Manji H, Mayberg H, Popoli M, Prochiantz A, Richter-Levin G, Somogyi P, Spedding M, Svenningsson P, Weinberger D (2007) How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discov 6:189-201. doi: 10.1038/nrd2217
2. Benjamini Y, Yekutieli D (2005) False discovery rate-adjusted multiple confidence intervals for selected parameters. J Am Stat Assoc 100:71. doi: 10.1198/016214504000001907
3. Benjamini Y, Lipkind D, Horev G, Fonio E, Kafkafi N, Golani I (2010) Ten ways to improve the quality of descriptions of whole-animal movement. Neurosci Biobehav Rev 34(8):1351-1365. doi: 10.1016/j.neubiorev.2010.04.004
4. Braida D et al (2009) Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br J Pharmacol 157:844-853
5. Broom DC et al (2002) Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. Psychopharmacology (Berlin) 164:42-48
6. Brunner D, Nestler E, Leahy E (2002) In need of high-throughput behavioral systems. Drug Discov Today 7(18 Suppl):S107-S112. doi: 10.1016/S1359-6446(02)02423-6
7. Carlezon WA Jr et al (2006) Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316:440-447
8. Conn PJ, Roth BL (2008) Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology 33:2048-2060. doi: 10.1038/sj.npp.1301638
9. Coryell W (1996) Psychotic depression. J Clin Psychiatry 57(Suppl 3):27-31, discussion 49
10. Crawley JN (2007) What's wrong with my mouse?: behavioral phenotyping of transgenic and knockout mice, 2nd edn. Wiley, Chichester
11. Crowley JJ, Blendy JA, Lucki I (2005) Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test. Psychopharmacology 183:257-264. doi: 10.1007/s00213-005-0166-5
12. Drai D, Golani I (2001) SEE: a tool for the visualization and analysis of rodent exploratory behavior. Neurosci Biobehav Rev 25:409-426. doi: 10.1016/S0149-7634(01)00022-7
13. Dubovsky SL, Thomas M (1992) Psychotic depression: advances in conceptualization and treatment. Hosp Community Psychiatry 43:1189-1198
14. Geyer MA, Russo PV, Masten VL (1986) Multivariate assessment of locomotor behavior: pharmacological and behavioral analyses. Pharmacol Biochem Behav 25(1):277-288
15. Golub TR et al (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531-537. doi: 10.1126/science.286.5439.531
16. Gunther EC, Stone DJ, Gerwien RW, Bento P, Melvyn PH (2003) Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro. Proc Natl Acad Sci U S A 100:9608-9613. doi: 10.1073/pnas.1632587100
17. Henry BL, Minassian A, Young J, Paulus MP, Geyer MA, Perry W (2010) Cross-species assessments of motor and exploratory behavior related to bipolar disorder. Neurosci Biobehav Rev 34:1296-1306. doi: 10.1016/j.neubiorev.2010.04. 002
18. Kafkafi N, Elmer GI (2005a) Texture of locomotor path: a replicable characterization of a complex behavioral phenotype. Genes Brain Behav 4(7):431-443. doi: 10.1111/j.1601-183X.2005.00126.x
19. Kafkafi N, Elmer GI (2005b) Activity density in the open field: a measure for differentiating the effect of psychostimulants. Pharmacol Biochem Behav 80(2):239-249. doi: 10.1016/j.pbb.2004.11.004
20. Kafkafi N, Benjamini Y, Sakov A, Elmer GI, Golani I (2005) Genotype-environment interactions in mouse behavior: a way out of the problem. Proc Natl Acad Sci U S A 102(12):4619-4624. doi: 10.1073/pnas.0409554102
21. Kafkafi N, Yekutieli D, Yarowsky P, Elmer GI (2008) Data mining in a behavioral test detects early symptoms in a model of amyotrophic lateral sclerosis. Behav Neurosci 122(4):777-787. doi: 10.1037/0735-7044.122.4.777
22. Kafkafi N, Yekutieli D, Elmer GI (2009) A data mining approach to in vivo classification of psychopharmacological drugs. Neuropsychopharmacology 34(3):607-623. doi: 10.1038/npp.2008.103
23. Koenig JI, Elmer GI, Shepard PD, Lee PR, Mayo C, Joy B, Hercher E, Brady DL (2005) Prenatal exposure to a repeated variable stress paradigm elicits behavioral and neuroendocrinological changes in the adult offspring: potential relevance to schizophrenia. Behav Brain Res 156(2):251-261
24. Nestler EJ, Hynan SE (2010) Animal models of neuropsychiatric disorders. Nat Neurosci 13:1161-1169. doi: 10.1038/nn.2647
25. Pangalos MN, Schechter LE, Hurko O (2007) Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 6(7):521-532. doi: 10.1038/nrd2094
26. Pataki CS, Feinberg DT, McGough JJ (2004) New drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs 9:293-302
27. Petit-Demouliere B, Chenu F, Bourin M (2005) Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology 177:245-255. doi: 10.1007/s00213-004-2048-7
28. Quan MN, Zhang N, Wang YY, Zhang T, Yang Z (2011) Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model. Neuroscience 182:88-97
29. Rihel J et al (2010) Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation. Science 327(5963):348-351. doi: 10.1126/science.1183090
30. Schopp DT (2011) Where will new neuroscience therapies come from? Nat Rev Drug Discov 10:715-716. doi: 10.1038/nrd3559
31. Schreiber S, Backer MM, Pick CG (1999) The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neurosci Lett 273:85-88
32. Tan PN, Steinbach M, Kumar V (2006) Introduction to data mining. Classification: basic concepts, decision trees and model evaluation. Addison-Wesley, Boston
33. Tecott LH, Nestler EJ (2004) Neurobehavioral assessment in the information age. Nat Neurosci 7:462-466. doi: 10.1038/nn1225
34. Willner P (2005) Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 52(2):90-110. doi: 10.1159/000087097